Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Psyadon Pharmaceuticals Inc.

Treating Tourette syndrome with a neuronal inhibitor

This article was originally published in Start Up

Executive Summary

No new drug has been developed for Tourette syndrome in more than 20 years. Almost all medications prescribed for the condition are given off-label, and none are particularly effective. News reported by Psyadon Pharmaceuticals Inc. in late July 2012 is encouraging to both the patient community and the start-up itself. Psyadon announced that an open-label Phase II study of its candidate ecopipam, which inhibits dopamine via the D1 receptor, was stopped after a planned interim data analysis because the data were strong enough to suggest the compound is conferring a genuine benefit.

Advertisement

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092362

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel